Return on Assets (ROA): 8.20%
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 8.20% is 52% below its 5-year average of 17.04%, near the low end of its 5-year range (7.84%–31.98%).
As of Sunday, June 28, 2026. 58.81% below its 12-month average of 19.91%.
EW Return on Assets (ROA) Chart
Annual fiscal-year return on assets; no daily interpolation.
EW Average Return on Assets (ROA) Chart
EW Current vs Average Return on Assets (ROA) Chart
EW Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
8.20%
RETURN ON ASSETS (ROA) AVG TTM
19.91%
RETURN ON ASSETS (ROA) AVG 3Y
18.29%
RETURN ON ASSETS (ROA) AVG 5Y
17.04%
RETURN ON ASSETS (ROA) AVG 10Y
15.24%
RETURN ON ASSETS (ROA) AVG 15Y
14.04%
RETURN ON ASSETS (ROA) AVG 20Y
12.43%
CURRENT VS TTM AVG
-58.81%
CURRENT VS 3Y AVG
-55.16%
CURRENT VS 5Y AVG
-51.86%
CURRENT VS 10Y AVG
-46.20%
CURRENT VS 15Y AVG
-41.58%
CURRENT VS 20Y AVG
-34.06%
EW Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 8.20% | 19.91% | 18.29% | 17.04% |
| Cencora, Inc. (COR)vs › | $55.67B | 3.12% | 2.14% | 2.52% | 0.85% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 2.75% | 2.42% | 0.86% | -0.71% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 2.24% | 3.00% | 3.04% | 2.95% |
| Humana Inc. (HUM)vs › | $46.08B | 2.04% | 2.52% | 4.20% | 5.49% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 32.35% | 29.29% | 27.30% | 27.52% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 10.82% | 11.40% | 12.40% | 16.97% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 8.01% | 5.66% | 4.50% | 3.49% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 10.82% | 10.56% | 11.14% | 10.55% |
| Medline Inc. (MDLN)vs › | $32.87B | 2.47% | 3.17% | 1.75% | 1.75% |
Asset Efficiency
ROA
8.2%
ROE
10.6%
Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The return on assets (ROA) for EW stock is 8.20%.
- Is Edwards Lifesciences Corporation's return on assets (ROA) high or low?
- The return on assets (ROA) of 8.20% is 52% below its 5-year average of 17.04%, near the low end of its 5-year range (7.84%–31.98%).
- What is the TTM average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The TTM average return on assets (ROA) for EW stock is 19.91%.
- What is the 3Y average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The 3Y average return on assets (ROA) for EW stock is 18.29%.
- What is the 5Y average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The 5Y average return on assets (ROA) for EW stock is 17.04%.
- What is the 10Y average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The 10Y average return on assets (ROA) for EW stock is 15.24%.
- What is the 15Y average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The 15Y average return on assets (ROA) for EW stock is 14.04%.
- What is the 20Y average return on assets (ROA) for Edwards Lifesciences Corporation (EW)?
- The 20Y average return on assets (ROA) for EW stock is 12.43%.
EW Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 7.84% |
| 2024-12-31 | 31.98% |
| 2023-12-31 | 14.98% |
| 2022-12-31 | 18.35% |
| 2021-12-31 | 17.68% |
| 2020-12-31 | 11.38% |
| 2019-12-31 | 16.14% |
| 2018-12-31 | 13.57% |
| 2017-12-31 | 10.92% |
| 2016-12-31 | 12.63% |
| 2015-12-31 | 12.19% |
| 2014-12-31 | 23.01% |
| 2013-12-31 | 14.38% |
| 2012-12-31 | 13.20% |
| 2011-12-31 | 11.95% |
| 2010-12-31 | 12.34% |
| 2009-12-31 | 14.18% |
| 2008-12-31 | 9.21% |
| 2007-12-31 | 8.40% |
| 2006-12-31 | 10.47% |
| 2005-12-31 | 6.45% |
| 2004-12-31 | 0.15% |
| 2003-12-31 | 7.17% |
| 2002-12-31 | 5.52% |
| 2001-12-31 | -1.23% |
| 2000-12-31 | -25.00% |
| 1999-12-31 | 5.71% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian